## Mansoor Amiji, Ph.D.

**Publications** ***(Please Note- Co-Authors are not listed. Full listing available upon request)***

***Books:***

**Applied Physical Pharmacy**. McGraw-Hill Medical Publishing Division. New York, NY. 2002.

**Polymeric Gene Delivery: Principles and Applications.** CRC Press, LLC (a subsidiary of Taylor and Francis). Boca Raton, FL. 2004.

**Nanotechnology for Cancer Therapy**. CRC Press, LLC (a subsidiary of Taylor and Francis). Boca Raton, FL. 2007.

**Biomedical Nanotechnology**, (10 Volumes Book Series). Volumes 1 and 2, *"Handbook of Materials for Nanomedicine"* Pan Stanford Publishing, Hackensack, NJ. (In press).

***Book Chapters:***

**Surface modification of polymeric biomaterials with poly(ethylene oxide): a steric repulsion approach**. In Shalaby, S.W., Ikada, Y., Langer, R., and Williams, J. (Eds.) *Polymers of Biological and Biomedical Significance*. American Chemical Society Symposium Series Publication, Volume 540. American Chemical Society, Washington, DC. 1994, pp 135-146.

**Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity.** In Cooper, S.L., Bamford, C.H., and Tsuruta, T. (Eds.) *Polymer Biomaterials: In Solution, as Interfaces, and as Solids*. VSP, The Netherlands. 1995, pp 535-552.

. **Albumin-modified biomaterial surfaces for reduced thrombogenicity**. In Wise, D.L., Altobelli, D.E., Grasser, J.D., Shwartz, E.R., Trantolo, D.J., and Yaszemski, M. (Eds.) *Encyclopedic Handbook of Biomaterials and Bioengineering - Part B Applications. Volume II*. Marcel Dekker, Inc., New York, NY. 1995, pp 1057-1070.

**Surface modification of chitosan to improve blood compatibility**. In Pandalai, S.G. (Eds.). *Recent Research Developments in Polymer Science, Volume III*. Transworld Research Network, Trivandrum, India. 1999, pp 31-39.

**Chitosan-based delivery systems: physicochemical properties and pharmaceutical applications**. In Dumitriu, S. (Eds.). *Polymeric Biomaterials. Second Edition, Revised and Expanded*. Marcel Dekker, Inc., New York, NY. 2001, Chapter 10, pp 213-238.

**Polymeric gene delivery systems**. In. Wise, D.L., Hasirci, V., Lewandrowski, K.-U., Yaszemski, M.J., Altobelli, D.W., and Trantolo, D.J. (Eds.). *Tissue Engineering and Novel Delivery Systems*. Marcel Dekker, Inc., New York, NY. 2004, Chapter 16, pp 333-367.

**Targeted drug delivery to tumor cells using colloidal carriers**. In Lu, D.R. and Oie, S. (Eds.). *Cellular Drug Delivery: Principles and Practice*. Humana Press, Inc., Totowa, NJ. 2004, Chapter 10, pp 181-215.

**Protein nanospheres for gene delivery**. In Amiji, M.M. (Ed.) *Polymeric Gene Delivery: Principles and Applications*. CRC Press, LLC. Boca Raton, FL. 2004, Chapter 27, pp. 429-447.

**Gelatin nanoparticles and their biofunctionalization**. In Kumar, C. (Ed.). *Nanotechnologies for the Life Sciences, Volume 2: Biological and Pharmaceutical Nanomaterials*. Wiley-VCH, Berlin, Germany. 2005, Chapter 11, pp. 330-353.

**Nanoparticles for delivery in the gastrointestinal tract**. In Torchilin, V.P. (Ed.). *Nanoparticulates as Drug Carriers*. Imperial College Press, London, United Kingdom, 2006, Chapter 26, pp 609-648.

**An overview of condensing and non-condensing polymeric systems for gene delivery**. In Friedmann, T. and Rossi, J (eds.). *Gene Transfer: Delivery and Expression of DNA and RNA – A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 2007, Chapter 34, pp 395-403.

**Protein nanospheres for gene delivery: preparation and *in vitro* transfection studies with gelatin nanoparticles**. In Friedmann, T. and Rossi, J. (Ed.). *Gene Transfer: Delivery and Expression of DNA and RNA – A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 2007, Chapter 52, pp 527-540.

**Long-circulating polymeric nanocarriers for drug and gene delivery in cancer**. In Amiji, M.M. (Ed.). *Nanotechnology for Cancer Therapy*. CRC Press, Boca Raton, FL. 2007, Chapter 13, pp 231-242.

**Nanoemulsions for tumor targeted drug delivery**. In Amiji, M.M. (Ed.). *Nanotechnology for Cancer Therapy*. CRC Press, Boca Raton, FL. 2007, Chapter 35, pp 723-739.

**Nanotechnology applications in cancer diagnosis and therapy**. In Yih, T.C. and Talpasanu, I. (Ed.). *Micro and Nano Manipulations for Biomedical Applications*. Springer Publishing, New York, NY, 2008, Chapter 2, pp 13-41.

**Multifunctional polymeric nanosystems for tumor-targeted delivery**. In Torchilin, V.P. (Ed.). *Multifunctional Pharmaceutical Nanocarriers*. Springer Publishing, New York, NY 2008, Chapter 2, pp 33-64.

**Multifunctional magnetic nanosystems for tumor imaging, targeted delivery, and thermal therapy**. In Torchilin, V.P. (Ed.). *Multifunctional Pharmaceutical Nanocarriers*. Springer Publishing, New York, NY 2008, Chapter 14, pp 381-408.

**Nanotechnology in oral drug delivery**. In Xu, J. J. and Ekins, S. (Eds.). *Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools*. Wiley Publishing, New York, NY (In press).

**Micro-spectral Imaging of Cells, and Applications Monitoring the Uptake of Drug Delivery Systems.** In Hollrichter, O. and Dieing, T. (Eds.). *Confocal Raman Imaging,* Springer Verlag, Heidelberg, Germany. (In press).

**Nanotechnology for targeted delivery of drugs and genes**. In Nalwa, H.S. (Ed.). *Encyclopedia of Nanoscience and Nanotechnology*, 2nd Edition, American Scientific Publishers, New York, NY. (In press).

**Polymeric nanoparticles as target-specific delivery systems.** In Amiji, M.M. and Torchilin, V.P. (Eds.). *Handbook of Materials for Nanomedicine: Volume 1*. Pan Stanford Publishing, Hackensack, NJ. (In press).

**Multifunctional stimuli-responsive nanoparticles for delivery of small and macromolecular therapeutics**. In Narang, A.S. and Mahato, R.I. (Eds.). *Targeted Delivery of Small and Macromolecular Drugs*. CRC Press, Inc., Boca Raton, FL (In press).

**Non-condensing type B gelatin-based delivery systems for systemic and local gene therapy**. In Morishita, M. and Park, K. (Eds.). *Biodrug Delivery Systems: Fundamentals, Applications, and Clinical Developments"*. Informa Healthcare Group, New York, NY (In press).

**Nanotechnology approaches for contrast enhancement in optical imaging and disease targeted therapy**. In Iftimia, N., Brugge, W., and Hammer, D.X (Eds.). *Advances in Optical Imaging for Clinical Medicine*, Chapter 16. Artec House Publishing, New York, NY (Submitted).

***Peer-Reviewed Articles:***

**Study on the prevention of surface-induced platelet activation by albumin coating**. *Journal of Biomaterials Science, Polymer Edition,* **3:** 375-388 (1992).

**Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers.** *Biomaterials* **13:** 682-692 (1992).

**Surface modification by radiation-induced grafting of PEO/PPO/PEO triblock copolymers**. *Journal of Colloid and Interface Science,* **155:** 251-255 (1993).

**Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity.** *Journal of Biomaterials Science, Polymer Edition,* **4:** 217-234 (1993).

**Hydrogel delivery system for vaginal and oral applications: formulation and biological considerations**. *Advances in Drug Delivery Reviews,* **11:** 137-167 (1993).

**Analysis on the surface adsorption of PEO/PPO/PEO triblock copolymers by radiolabelling and fluorescence techniques.** *Journal of Applied Polymer Science,* **52:** 539-544 (1994).

**Permeability and blood compatibility properties of chitosan-poly(ethylene oxide) blend membranes for hemodialysis.** *Biomaterials,* **16:** 593-599 (1995).

**Pyrene fluorescence study of chitosan self-association in aqueous solution**. *Carbohydrate Polymers* **26:** 211-213 (1995).

**Photophysical characterization of insulin denaturation and aggregation at hydrophobic interfaces**. *Drug Development and Industrial Pharmacy,* **21:** 1661-1669 (1995).

**pH-sensitive swelling and drug release properties of chitosan-poly(ethylene oxide) semi-interpenetrating polymer network.** In R. Ottenbrite, S. Huang, and K. Park (eds.) *Hydrogels and Biodegradable Polymers for Bioapplications*. American Chemical Society Symposium Series Publication. Volume 627. American Chemical Society, Washington, DC. 1996, pp 209-220.

**Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach.** *Pharmaceutical Research* **13:** 588-593 (1996).

**Surface modification of chitosan membranes by complexation-interpenetration of anionic polysaccharides for improved blood compatibility in hemodialysis**. *Journal of Biomaterials Science, Polymer Edition,* **8:** 281-298 (1996).

**Gelatin-poly(ethylene oxide) semi-interpenetrating polymer network with pH-sensitive swelling and enzyme-degradable properties for oral drug delivery**. *Drug Development and Industrial Pharmacy,* **23:** 575-582 (1997).

**Synthesis of anionic poly(ethylene glycol) derivative for chitosan surface modification in blood-contacting applications.** *Carbohydrate Polymers,* **32:** 193-199 (1997).

**Platelet adhesion and activation on an amphoteric chitosan derivative bearing sulfonate groups**. *Colloids and Surfaces. Part B: Biointerfaces,* **10:** 263-271 (1998).

**Synthesis of fluorescent chitosan derivative and its application for the study of chitosan-mucin interactions**. *Carbohydrate Polymers* **38:** 99-107 (1999).

**Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for *Helicobacter pylori* infection.** *Journal of Pharmacy and Pharmacology,* **51:** 667-672 (1999).

**Chitosan-Pluronic® physical interpenetrating network: membrane fabrication and protein permeability studies.** In M. El-Nokaly and H. Soini (eds.). *Polysaccharides in Pharmaceutical and Cosmetic Applications*. American Chemical Society Symposium Series Publication, Volume 737. American Chemical Society, Washington, DC 1999, pp 178-186.

**Surface and blood interaction properties of poly(ethylene oxide)-modified chitosan microspheres.** *S.T.P Pharma Sciences*. **10:** 95-100 (2000). [Year 2000 thematic issue on *"Chitosan in Drug Delivery Systems"*]

**Evaluation of the permeability and blood-compatibility properties of membranes formed by physical interpenetration of chitosan with PEO/PPO/PEO triblock copolymers.** *Journal of Applied Polymer Science,* **80:** 1274-1284 (2001).

**Preparation and evaluation of sustained drug release from Pluronic® polyol rectal suppositories**. *International Journal of Pharmaceutical Compounding,* **5:** 234-237 (2001).

**pH-responsive biodegradable polymer microspheres: rapid release of encapsulated material within the range of intracellular pH**. *Angewandte Chemie, International Edition,* **40(9):** 1707-1710 (2001).

**Intratumoral administration of paclitaxel in an *in situ* gelling poloxamer 407 formulation.** *Pharmaceutical Development and Technology,* **7(2):** 195-202 (2002).

**Stomach-specific anti-*H. pylori* therapy. I: Preparation and characterization of tetracycline-loaded chitosan microspheres.** *International Journal of Pharmaceutics,* **235(1-2):** 87-94 (2002).

**Localized delivery of paclitaxel in solid tumors from biodegradable chitin microparticle formulations**. *Biomaterials,* **23(13):** 2723-2731 (2002).

**Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery.** *Pharmaceutical Research,* **19 (7):** 1062-1068 (2002).

**Surface-modified polymeric nanoparticles for tumor-targeted delivery.** ***surFACTS*** *– Official Newsletter of Surfaces in Biomaterials Foundation*. **7(2):** 1-6 (2002).

**Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen**. *International Journal of Pharmaceutics,* **249 (1-2):** 127-138 (2002).

**Perm-selective chitosan-alginate hybrid microcapsules for enzyme immobilization technology.** *Pharmaceutical Engineers – Journal of the International Society of Pharmaceutical Engineers*. **22 (6):** 112-114 (2002).

**Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as pH-sensitive biodegradable system for paclitaxel delivery**. *Journal of Controlled Release*, **86:** 223-234 (2003).

**Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles.** *AAPS PharmSci*, **5 (1):** Article 3 (2003). (available online at http://www.aapspharmaceutica.org).

**Chitosan-based gastrointestinal delivery systems** *Journal of Controlled Release*, **89:** 151-165 (2003). – Invited review.

**Stomach-specific anti-*H. pylori* therapy. II: Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils.** *Pharmaceutical Development and Technology*, **8:** 253-262 (2003).

**Poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery**. *Pharmaceutical Engineers – Journal of the International Society of Pharmaceutical Engineers*. **23 (5):** 108-114 (2003).

**Enzyme immobilization in novel alginate-chitosan core-shell microcapsules.** *Biomaterials*, **25 (10):** 1937-1945 (2004).

**Stomach-specific anti-*H. pylori* therapy. III: Effect of chitosan microsphere crosslinking on the gastric residence and local tetracycline concentrations in fasted gerbils.** *International Journal of Pharmaceutics*, **272 (1-2):** 99-108 (2004).

**Poly(N-acetyl-glucosamine)-mediated red blood cell interactions.** *Journal of Trauma – **Injury Infection** and **Critical Care***, 57(1): Supplement: S7-S12 (2004).

**Biodistribution and targeting potential of poly(ethylene glycol) modified gelatin nanoparticles in subcutaneous murine tumor model.** *Journal of Drug Targeting*, **12(9-10):** 585-591 (2004).

**Cellular interactions and *in vitro* DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles.** *Journal of Pharmaceutical Sciences* **94 (1):** 184-198 (2005).

**Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted tamoxifen delivery in breast cancer.** *International Journal of Pharmaceutics*, **293:** 261-270 (2005). [This publication was recognized with a **Certificate of Most Cited Publication** by the International Journal of Pharmaceutics publishing team].

**Tumor-targeted delivery of plasmid DNA using poly(ethylene glycol)-modified gelatin nanoparticles: *In vitro* and *in vivo* studies.** *Pharmaceutical Research*, **22(6):** 951-961 (2005). [This publication was recognized for the **2007 Meritorious Manuscript Award** from the American Association of Pharmaceutical Scientists].

**Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs:** Part I. *In vitro* evaluations. *Molecular Pharmaceutics*, **2(5):** 357 -366 (2005).

**Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione.** *Bioconjugate Chemistry*, **16 (6):**1423-1432 (2005).

**Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part II.** *In vivo* biodistribution and tumor localization studies. *Pharmaceutical Research*, **22(12):** 2107-2114 (2005).

**Long-circulating nanovectors for tumor-specific gene delivery.** *Technology in Cancer Research and Treatment*, **4(6):** 615-625 (2005). (**Invited review** in the special issue on *"Nanotechnology in Cancer Detection and Treatment"*).

**An approach to heterobifunctional poly(ethylene glycol) bioconjugates.** *Bioorganic and Medicinal Chemistry Letters*, **15:** 5558-5561 (2005).

**Bhavsar, M.D., Tiwari, S.B., and Amiji, M.M. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design.** *Journal of Controlled Release*, **110(2):** 422-430 (2006). [This publication was **One of 25 Most Cited Publications** in the Journal of Controlled Release website, http://top25.sciencedirect.com/index.php?cat_id=7&subject_area_id=20&journal_id=01683659].

**Surface functionalization of gold nanoparticles using hetero-bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery.** *International Journal of Nanomedicine*, **1(1):** 51-57 (2006).

**Multifunctional polymeric nanoparticles for tumor-targeted drug delivery.** *Expert Opinion on Drug Delivery*, **3(2):** 205-216 (2006).

***Current Drug Delivery,* 3: 219-232 (2006).** Invited review.

**Improved oral delivery of paclitaxel following administration in nanoemulsion formulations.** *Journal of Nanoscience and Nanotechnology*, **6(9-10):** 3215-3221 (2006). (**Invited publication** for the special issue on *"Nanotechnology in Advanced Drug Delivery"*).

**Engineered nanosystems for targeted delivery of drugs and genes** – *Future Drug Delivery 2006*, Touch Briefings(2006). (Invited review available online at http://www.touchbriefings.com/cdps/cditem.cfm?cid=5&nid=1859). **Invited review.**

**Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.** *Expert Opinion on Drug Delivery*, **3(5):** 613-628 (2006).

**Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. *Pharmaceutical Research,* 23(11): 2638-2645 (2006).**

**Preparation and *in vitro* characterization of multifunctional nanoemulsions for simultaneous MR imaging and targeted drug delivery**. *Journal of Biomedical Nanotechnology*, **2(3-4):** 217–224 (2006).

**Formulation and physiological factors influencing CNS delivery upon intranasal administration**. *Critical Reviews in Therapeutic Drug Carrier Systems*, **23(4): 3**19-347 (2006).

**Role of nanotechnology in the treatment of HIV/AIDS: potential to overcome viral reservoir challenge.** *Discovery Medicine*, **6(34):** 157-162 (2006). **Invited review.**

**Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs:** Part III. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. *Cancer Chemotherapy and Pharmacology*, **59 (4):** 477-484 (2007).

**Tetracycline-containing chitosan microspheres for localized treatment of *Helicobacter pylori* infection**. *Cellulose*, **14:** 3-14 (2007) (**Invited review** for *"Special Issue on Polysaccharides in Drug Delivery"*).

**Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice.** *Journal of Pharmaceutical Sciences,* **96(2):** 397-407 (2007).

**Nanocarriers for systemic and mucosal vaccine delivery.** *Recent Patents on Drug Delivery and Formulation,* **1(1):** 1-9 (2007*).* **Invited review.**

**Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery.** *Nanomedicine: Nanotechnology, Biology and Medicine,* **3(1):** 32-42 (2007).

**Antiangiogenic gene therapy with systemically-administered *sFlt-1* plasmid DNA in engineered gelatin-based nanovectors.** *Cancer Gene Therapy,* **14(5):** 488-498 (2007).

**Nanotechnology-based delivery systems in HIV/AIDS therapy**. *Future Medicine – Future HIV Therapy*, **1(1):** 49-59 (2007). **Invited review.**

**Polymeric nano- and microparticle technologies for oral gene therapy**. *Expert Opinion on Drug Delivery,* **4(3):** 197-213 (2007).

**Modulation of intracellular ceramide with polymeric nanoparticles to overcome multi-drug resistance in cancer.** *Cancer Research,* **67(10):** 4843-4850 (2007).

**Gastrointestinal distribution and *in vivo* gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS).** *Journal of Controlled Release*, **119(3):** 339-348 (2007).

**A multifunctional polymeric nanoparticle strategy for modulation of drug resistance in cancer.** *Pharmaceutical Engineers – Journal of the International Society of Pharmaceutical Engineers*. **27(3):** 1-7 (2007).

**Poly(ethylene glycol)-modified polymeric nanocarriers for tumor-targeted and intracellular delivery**. *Pharmaceutical Research,* **24(8):** 1407-1414 (2007). **Invited expert review.**

**Synthesis and evaluations of tripodal peptide analogues for cellular delivery of phosphopeptides**. *Journal of Medicinal Chemistry*, **50:** 3604-3617 (2007).

**A review of nanoparticulate carriers for the treatment of coronary restenosis.** *International Journal of Nanomedicine,* **2(2):** 1-19 (2007).

**The role of nanotechnology in pharmaceutical product development. *Journal of Pharmaceutical Sciences,* 96(10): 2547 – 2565 (2007). Invited review.**

**Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome multidrug resistance in ovarian cancer.** *International Journal of Cancer,* **121(8):** 1830-1838 (2007).

**Nanotechnology: Improving targeted delivery** – *Touch Briefing's Future Drug Delivery 2007*. (Invited review available online at http://www.touchbriefings.com/cdps/cditem.cfm?cid=5&nid=2514). Invited review.

**Improved oral bioavailability and brain transport of saquinavir upon administration in nanoemulsion formulations.** *International Journal of Pharmaceutics*, **347:** 93–101 (2008).

**A review of stimuli responsive nanocarriers for drug and gene delivery.** *Journal of Controlled Release*. 126(3): 187-204 (2008).

**Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract.** *AAPS PharmSciTech*, **9(1):** 288-294 (2008).

**Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice.** *Journal of Drug Targeting*, **16(4):** 302-310 (2008).

**Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.** *Clinical Cancer Research* **14(10):** 3193-3203 (2008).

**Polymeric nanosystems for site-specific drug and gene delivery.** *European Journal of Nanomedicine*, **1(1):** 6-14 (2008). (Invited review publication in the inaugural journal issue based on "*2008 European Conference on Clinical Nanomedicine"*).

**Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in cancer cells.** *Journal of Biomedical Nanotechnology*, **4:** 165–173 (2008).

**Cytotoxicity and apoptosis enhancement in brain tumor cells upon co-administration of paclitaxel and ceramide in nanoemulsion formulations**. *Journal of Pharmaceutical Sciences*. **97(7):** 2745-2756 (2008).

**Poly(beta-amino ester) and cationic phospholipid-based lipopolyplexes for gene delivery and transfection in human aortic endothelial and smooth muscle cells.** *Biomacromolecules*, **9(4):** 1179-1187 (2008).

**Enhancement in anti-proliferative effect of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles.** *Pharmaceutical Research*, **25(8):** 1936-1947 (2008).

**Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease**. *Gene Therapy*, **15(17):** 1200-1209 (2008).

**Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multi-functional polymer blend nanoparticles in drug resistant breast cancer model.** *Molecular Pharmaceutics*, **5(4):** 516-526 (2008). (Invited publication in the Special issue on "*Biodistribution of Nanomedicines"*).

**Multi-functional nanocarriers for targeted delivery of drugs and genes**. *Journal of Controlled Release*, **130(2):** 121-128 (2008). (**Invited publication** in the Special issue on "*2007 Nano-Drug Delivery Systems Conference"*).

**A model predicting delivery of saquinavir in nanoparticles to human monocytes/macrophage (Mo/Mac) cells.** *Biotechnology and Bioengineering*, **101(5):** 1072-1082 (2008).

**Multi-functional nanocarriers to overcome tumor drug resistance.** *Cancer Treatment Reviews*, **34(7):** 592-602 (2008).

**Epidermal growth factor receptor-targeted gelatin-based engineered nanocarrier systems for DNA delivery and transfection in human pancreatic cancer cells.** *The AAPS Journal*, **10(4):** 565-576 (2008).

**Evaluations of combination *mdr-1* gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.** *Cancer Chemotherapy and Pharmacology*, **63(4):** 711-722 (2009).

**Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.** *Expert Opinion on Drug Delivery*, (In press).

**Co-administration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.** *Molecular Pharmaceutics*, (In press).

**In vitro and in vivo studies of local arterial gene delivery and transfection using lipopolyplexes-embedded stents.** *Journal of Biomedical Materials Research, Part A*., (Submitted).

**Nanoparticle-based photodynamic treatment of *Enterococcus faecalis* in planktonic phase versus endodontic biofilms.** *Antimicrobial Agents and Chemotherapy*. (Submitted).

**Overcoming tumor multidrug resistance using ceramide co-therapy in temporal-controlled polymer blend nanoparticle delivery systems.** *Molecular Cancer Therapeutics*, (Submitted).

**Nanoporous inorganic membranes or coatings for sustained drug delivery from implantable devices**. *Advanced Drug Delivery Reviews*, (Submitted).

**Delivery strategies to enhance mucosal vaccination**. *Expert Opinion on Biological Therapy*, (Submitted).

**Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis**. *Molecular Therapy*, (Submitted).

**Brain delivery of proteins by the intranasal route of administration using cationic liposomes**. *Journal of Controlled Release*, (Submitted).

***Conference Abstracts:***

**Adsorption isotherms of doxorubicin on oxidized dextran**. *Pharmaceutical Research* **5:** S-143 (1988).

**Mucoadhesive hydrogels effective at neutral pH**. *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* **16:** 217-218 (1989).

**The minimum amount of biologically active fibrinogen necessary for surface-induced platelet activation.** *Transactions of the Society for Biomaterials* **13:** 137 (1990).

**Mechanism of surface passivation by albumin**. *Proceedings of the Cardiovascular Science and Technology Conference: Basic and Applied* **5:** 245-247 (1990).

**Mechanism study on the prevention of surface-induced platelet activation by adsorbed albumin**. *Transactions of the Surfaces in Biomaterials '91 Symposium* **1:** 1-5 (1991).

**Prevention of protein adsorption and platelet adhesion by steric repulsion**. *Transactions of the Society for Biomaterials* **14:** 41 (1991).

**Surface passivating effect of PEO/PPO/PEO triblock copolymers**. *Polymer Preprints* **33:** 501-502 (1992).

**Analysis on the surface adsorption of PEO/PPO/PEO triblock copolymers**. *Proceedings of the American Chemical Society: Division of Polymeric Materials, Science, and Engineering* **67:** 211 (1992).

**Prevention of protein adsorption on surfaces by PEO/PPO/PEO triblock copolymers**. *Pharmaceutical Research* **9:** S-115 (1992).

**Adsorption behavior of PEO/PPO/PEO triblock copolymers on DDS-glass**. *Transactions of the Society for Biomaterials* **17:** 137 (1994).

**Development of poly(ethylene oxide)-chitosan blend membranes for hemodialysis**. *Transactions of the Society for Biomaterials* **17:** 108 (1994).

**Chitosan-poly(ethylene oxide) semi-IPN as a pH-sensitive drug delivery system**. *Polymer Preprints* **35:** 403-404 (1994).

**Pyrene fluorescence study of insulin denaturation and aggregation at hydrophobic interfaces**. *Pharmaceutical Research* **11:** S-81(1994).

**Chitosan-poly(ethylene oxide) hydrogels for pH-sensitive oral drug delivery.** *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials*. **22:** 330-331 (1995).

**Site-specific oral delivery of antibiotics using pH-sensitive hydrogels**. *Proceedings of the American Chemical Society's Conference on Formulations and Drug Delivery* **1:** 38 (1995).

**Surface modification of chitosan hemodialysis membranes with anionic polysaccharides**. *Transactions of the Fifth World Biomaterials Congress*. **1:** 879 (1996).

**Modification of chitosan membrane surfaces by the complexation-interpenetration of anionic polysaccharides**. *Transactions of the Surfaces in Biomaterials '96 Symposium* **6:** 108-112 (1996).

**Amiji, M.M.** Chitosan surface modification with anionic poly(ethylene glycol) derivative for improved blood compatibility. *Proceedings of the First International Symposium on Advanced Biomaterials* **1:** 73 (1997).

**The role of gastric pH and mucin permeability on localized antibiotic delivery for *H. pylori* infection.** *Pharmaceutical Research* **14:** S-707 (1997).

**Mucoadhesive chitosan microspheres for stomach-specific antibiotic delivery**. *Pharmaceutical Research* **14:** S-711 (1997).

**Surface modification of chitosan by polyelectrolyte complexation-interpenetration to improve biocompatibility.** *Pharmaceutical Research* **14:** S-151 (1997).

**Surface modification of chitosan microspheres to improve biocompatibility**. *Transactions of the Society for Biomaterials*. **22:** 239 (1999).

**Novel thermogelling paclitaxel formulation for localized delivery**. *Transactions of the Society for Biomaterials*. **22:** 321 (1999).

**Membranes formed by physical interpenetration of chitosan with PEO/PPO/PEO triblock copolymers**. *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* **26:** 320 (1999).

**Preparation and characterization of cross-linked chitosan microspheres for delivery of tetracycline locally in the stomach.** *AAPS PharmSci Supplement* **2:** (2000).

**Permselective membranes prepared by physical interpenetration of chitosan with PEO/PPO/PEO triblock copolymers.** *Proceedings of the American Association of Pharmaceutical Scientists – Pharmaceutical Congress of the Americas*. **1:** 114 (2001).

**Intratumoral administration of paclitaxel in a thermogelling Pluronic® F-127 formulation**. *Proceedings of the American Association of Pharmaceutical Scientists – Pharmaceutical Congress of the Americas*. **1:** 129 (2001).

**Biodegradable chitin-paclitaxel microparticle formulations for localized drug delivery**. *Proceedings of the American Association of Pharmaceutical Scientists – Pharmaceutical Congress of the Americas*. **1:** 129 (2001).

**Poly(epsilon-caprolactone) nanoparticles for intracellular delivery of tamoxifen**. *AAPS PharmSci Supplement* **3:** (2001).

**Perm-selective alginate-chitosan hybrid microcapsules for enzyme immobilization**. *AAPS PharmSci Supplement* **3:** (2001).

**Design and *in vitro* evaluation of colon specific delivery system for budesonide, a novel glucocorticoid**. *AAPS PharmSci Supplement* **3:** (2001).

**Cellular uptake, trafficking, and DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles.** *AAPS PharmSci Supplement* **4:** (2002).

**Polymeric nanoparticles for targeted and controlled tamoxifen delivery in breast cancer: *in-vitro* and *in-vivo* investigations.** *AAPS PharmSci Supplement* **6:** (2004).

**Preparation of thiolated gelatin nanoparticles for rapid intracellular delivery in response to glutathione.** *AAPS PharmSci Supplement* **6:** (2004).

**Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in tumor-bearing mice.** *AAPS PharmSci Supplement* **6:** (2004).

**Nanoparticles-in-microsphere hybrid systems for oral DNA vaccine delivery.** *AAPS PharmSci Supplement* **6:** (2004).

**Biomedical applications of gold nanoparticles functionalized using hetero-bifunctional poly(ethylene glycol) spacer.** *Materials Research Society Symposium Proceedings (Nanoscale Materials Science in Biology and Medicine),* **845:** 223-228 (2005).

**Biodistribution and tumor-targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles.** *Materials Research Society Symposium Proceedings, (Nanoscale Materials Science in Biology and Medicine),* **845:** 229-235 (2005).

**Biodegradable polymeric nanoparticles for tumor-selective tamoxifen delivery: In vitro and In vivo studies.** *Materials Research Society Symposium Proceedings (Nanoscale Materials Science in Biology and Medicine),* **845:** 369-373 (2005).

**Gold and iron-gold nanoparticles for intracellular tracking and *in vivo* medical applications.** ***Proceedings of the American Physical Society Meeting* (2005).**

**Hetero-bifunctional poly(ethylene glycol) modified gold nanoparticles as an intracellular tracking and delivery agent.** *Proceedings of the NSTI Nanotech 2005, NSTI Nanotechnology Conference and Trade Show*, Anaheim, CA, May 8-12, (2005).

**Superparamagnetic iron oxide-gold core-shell nanoparticles for biomedical applications**. *Proceedings of the NSTI Nanotech 2005, NSTI Nanotechnology Conference and Trade Show*, Anaheim, CA, May 8-12, (2005).

**Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design.** *The AAPS Journal,* **7:** No. S2, Abstract W4128 (2005).

**Formulation development and *in vivo* biodistribution studies of poly(ethylene glycol)-modified thiolated gelatin nanoparticles.** *The AAPS Journal,* **7: S2**, Abstract W5088 (2005).

**Novel nanoemulsions for improved oral delivery of hydrophobic drugs.** *The AAPS Journal,* **7: S2,** Abstract M1184 (2005).

**Application of statistical factorial design for the preparation of poly(styrene-b-isobutylene-b-styrene) triblock copolymer microspheres**. *The AAPS Journal,* **7: S2**, Abstract R6151 (2005).

**Nanomedicine: a new paradigm in diagnosis and therapy**. *Proceedings of SPIE-The International Society for Optical Engineering* **6008:** 247-254 (2005).

**Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in tumor cells.** *Transactions of the Society for Biomaterials,* (2006).

**Development of the nanoparticles-in-microsphere hybrid formulations for oral delivery of plasmid DNA.** *Transactions of the Society for Biomaterials,* (2006).

**Novel nanoemulsions for improved oral delivery of hydrophobic drugs**. *Transactions of the Society for Biomaterials,* (2006).

**Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in tumor cells**. *Proceedings of the NSTI Nanotech 2006, NSTI Nanotechnology Conference and Trade Show*, Boston, MA May 8-12, (2006).

**Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery systems using factorial design.** *Proceedings of the NSTI Nanotech 2006, NSTI Nanotechnology Conference and Trade Show*, Boston, MA May 8-12, (2006).

**Novel nanoemulsions for improved oral delivery of poorly soluble drugs.** *Proceedings of the NSTI Nanotech 2006, NSTI Nanotechnology Conference and Trade Show*, Boston, MA May 8-12, (2006).

**Characterization and in vivo biodistribution studies with poly(ethylene glycol)-modified thiolated gelatin nanoparticles.** *Proceedings of the NSTI Nanotech 2006, NSTI Nanotechnology Conference and Trade Show*, Boston, MA May 8-12, (2006).

**Nanotechnology for drug delivery: an overview**. *Proceedings of the NSTI Nanotech 2006, NSTI Nanotechnology Conference and Trade Show*, Boston, MA May 8-12, (2006).

**Poly(styrene-*b*-isobutylene-*b*-styrene) triblock copolymer microspheres for sustained release drug delivery.** *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* **33:** (2006).

**Multifunctional nanosystems to overcome drug resistance in cancer**. *Proceedings of the First National Cancer Institute's Alliance in Nanotechnology Meeting*. San Diego, CA October 24-26, pp 17 (2006).

**Modulation of multidrug resistance in cancer with polymer blend nanoparticles.** *Proceedings of the First National Cancer Institute's Alliance in Nanotechnology Meeting*. San Diego, CA October 24-26, pp 30 (2006).

**Brain delivery of proteins by the intranasal route of administration using cationic liposomes.** *Proceedings of the Society of Neuroscience Meeting,* Atlanta, GA (2006).

**Tumor-targeted delivery of hydrophobic drugs in pH-sensitive poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles.** *The AAPS Journal,* **8:** S2, (2006).

**Development and characterization of nanoemulsion formulations containing multimodal therapeutics for brain tumor.** *The AAPS Journal,* **8:** S2, (2006).

**Biodegradable polymeric nanoparticles for intracellular saquinavir delivery in HIV/AIDS.** *The AAPS Journal,* **8:** S2, (2006).

**Oral plasmid DNA administration and transfection using nanoparticles-in-microsphere formulations**. *The AAPS Journal,* **8:** S2, (2006).

**Modulation of multidrug resistance in cancer with polymer blend nanoparticles.** *The AAPS Journal,* **8:** S2, (2006).

**Tumor-targeted *sFlt-1* gene delivery using long-circulating thiolated gelatin nanoparticles.** *The AAPS Journal,* **8:** S2, (2006).

**Improved oral delivery of saquinavir in nanoemulsion formulations for HIV/AIDS.** *The AAPS Journal,* **8:** S2, (2006).

**Nanotechnology for targeted drug and gene delivery**. *Nanomedicine: Nanotechnology, Biology and Medicine*, **2(4):** 299-300 (2006).

**Nanotechnology in cancer diagnosis, imaging, and therapy**. *Proceedings of the American College of Veterinary Pathologists 57th Annual Meeting and the American Society for Veterinary Clinical Pathology 41st Annual Meeting,* pp 4-7 *(2006)*.

**Gastrointestinal gene delivery in mice using polymeric nanoparticles-in-microsphere oral system**. *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* (2007).

**Design and development of a polymer-blend nanoparticle drug delivery system to overcome multidrug resistance in cancer.** *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* (2007).

**Paclitaxel and ceramide combination therapy in biodegradable polymeric nanoparticles to overcome multidrug resistance in cancer.** *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* (2007).

**Modulation of intracellular ceramide metabolism with biodegradable polymeric nanoparticle-encapsulated tamoxifen to overcome multidrug resistance in cancer**. *The AAPS Journal,* **9:** S2, (2007).

**Multifunctional polymer blend nanoparticles for temporal-controlled release of combination therapeutics to overcome multidrug resistance of cancer**. *The AAPS Journal,* **9:** S2, (2007).

**Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract.** *The AAPS Journal,* **9:** S2, (2007).

**HER2/neu receptor-targeted engineered gelatin nanovectors for gene delivery and transfection in pancreatic cancer cells.** *The AAPS Journal,* **9:** S2, (2007).

**Gene delivery and transfection studies with lipopolyplexes in human endothelial and smooth muscle cells**. *Proceedings of the American Chemical Society: Division of Polymeric Materials, Science, and Engineering* **78:** (2008).

**Gene delivery and transfection studies with lipopolyplexes in human endothelial and smooth muscle cells.** *Proceedings of the NSTI Nanotech 2008, NSTI Nanotechnology Conference and Trade Show*, Boston, MA June 1-5, (2008).

**Epidermal growth factor receptor-targeted engineered gelatin nanovectors for gene delivery and transfection in pancreatic cancer cells.** *Proceedings of the NSTI Nanotech 2008, NSTI Nanotechnology Conference and Trade Show*, Boston, MA June 1-5, (2008).

**Non-condensing calcium alginate microspheres for macrophage-selective gene delivery and transfection.** *Proceedings of the NSTI Nanotech 2008, NSTI Nanotechnology Conference and Trade Show*, Boston, MA June 1-5, (2008).

**Multifunctional nanoparticulate system for simultaneous *EGFR* gene silencing and enhancement of apoptosis in pancreatic cancer cells.** *Proceedings of the NSTI Nanotech 2008, NSTI Nanotechnology Conference and Trade Show*, Boston, MA June 1-5, (2008).

**Gene delivery and transfection studies in smooth muscle cells with lipopolyplexes immobilized in gelatin-coated stainless steel substrates.** *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* (2008).

**Cellular trafficking studies of ceramide-loaded poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles with Raman spectroscopy.** *Proceedings of the International Symposium on the Controlled Release of Bioactive Materials* (2008).

**Epidermal growth factor receptor-targeted gelatin-based nanoparticles for reporter and therapeutic gene delivery in human pancreatic cancer cells.** *The AAPS Journal,* **10:** S2, (2008).